Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
Authors
Keywords
-
Journal
BMC CANCER
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-09
DOI
10.1186/s12885-018-5228-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Castration Induces Up-Regulation of Intratumoral Androgen Biosynthesis and Androgen Receptor Expression in an Orthotopic VCaP Human Prostate Cancer Xenograft Model
- (2014) Matias Knuuttila et al. AMERICAN JOURNAL OF PATHOLOGY
- Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
- (2014) Maria Thadani-Mulero et al. CANCER RESEARCH
- Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation
- (2014) Relja Popovic et al. PLoS Genetics
- Role of EZH2 in the Growth of Prostate Cancer Stem Cells Isolated from LNCaP Cells
- (2013) Kuiqing Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer
- (2013) Y. Zhu et al. MOLECULAR CANCER THERAPEUTICS
- Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
- (2013) T Karantanos et al. ONCOGENE
- EZH2, an epigenetic driver of prostate cancer
- (2013) Yeqing Angela Yang et al. Protein & Cell
- Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer
- (2012) Irfan A. Asangani et al. MOLECULAR CELL
- Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM
- (2012) Dejuan Kong et al. PLoS One
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- EZH2 Is Required for Breast and Pancreatic Cancer Stem Cell Maintenance and Can Be Used as a Functional Cancer Stem Cell Reporter
- (2012) Lilian E. van Vlerken et al. Stem Cells Translational Medicine
- Overcoming docetaxel resistance in prostate cancer: a perspective review
- (2012) Clara Hwang Therapeutic Advances in Medical Oncology
- Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review
- (2011) Giuseppe Colloca et al. MEDICAL ONCOLOGY
- Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
- (2011) Amanda J O'Neill et al. Molecular Cancer
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
- (2010) M.-L. Zhu et al. CANCER RESEARCH
- MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β
- (2010) Paul Cao et al. Molecular Cancer
- Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
- (2010) Christoph W. M. Reuter et al. WORLD JOURNAL OF UROLOGY
- Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
- (2008) Mari Nakabayashi et al. BJU INTERNATIONAL
- Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells
- (2008) Francesco Fabbri et al. JOURNAL OF CELLULAR PHYSIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now